Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication

NCT00102050 is registered in ClinicalTrials.gov with Nissan Chemical Industries as lead sponsor.

NCT NCT00102050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication
Lead sponsor
Nissan Chemical Industries
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
April 30, 2006
Enrollment
390
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

intermittent claudication, peripheral vascular disease